Streptokinase

Overview

Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

Indication

For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae

Associated Conditions

Acute Myocardial Infarction (AMI)
Arterial Thromboembolism
Arterial thrombosis
Arteriovenous fistula occlusion
Arteriovenous fistula thrombosis
Arteriovenous occlusions
Central Retinal Vein Occlusion (CRVO)
Chronic Occlusive Arterial Disease
Deep Vein Thrombosis
Peripheral artery thrombosis
Pulmonary Embolism
Pulmonary Embolism Acute Massive
Pulmonary Thromboembolism
Acute Arterial Thromboembolism

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism	2024/08/09	NCT06545864	N/A	Not yet recruiting	Assiut University
Catheter Directed Interventions in Pulmonary Embolism	2018/07/23	NCT03595085	Not Applicable	UNKNOWN	Assiut University
Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS	2018/03/14	NCT03465085	Phase 3	Completed	Beni-Suef University
Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital	2017/06/01	NCT03172052	Phase 4	UNKNOWN	Assiut University
Acute Coronary Syndrome Sri Lanka Audit Project	2016/09/08	NCT02893280	N/A	Withdrawn	University of Colombo
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)	2014/07/08	NCT02182011	Phase 3	Completed	Boehringer Ingelheim
Asia Africa Streptokinase Trial	2014/05/30	NCT02150785	Phase 2	Withdrawn	University of Alberta
Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis	2013/11/06	NCT01977118	Phase 2	Completed	Post Graduate Institute of Medical Education and Research, Chandigarh
Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis	2011/10/13	NCT01451320	Not Applicable	Completed	Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
A Trial Using Double-Bolus THR-100 Versus Streptokinase	2011/02/28	NCT01305226	Phase 3	Completed	Bharat Biotech International Limited

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
STREPTASE INJ 250000UNIT/VIAL	hoechst canada inc.	00527157	Powder For Solution - Intravenous	250000 UNIT / VIAL	12/31/1981
STREPTASE INJ 750000UNIT/VIAL	hoechst canada inc.	00527149	Powder For Solution - Intravenous	750000 UNIT / VIAL	12/31/1981
STREPTASE	csl behring canada inc	02019000	Powder For Solution - Intravenous , Intracoronary	750000 UNIT / VIAL	12/31/1994
STREPTASE	csl behring canada inc	02018993	Powder For Solution - Intracoronary , Intravenous	250000 UNIT / VIAL	12/31/1994
STREPTASE INJ 1500000 UNIT/VIAL	hoechst canada inc.	00881686	Powder For Solution - Intravenous	1500000 UNIT / VIAL	12/31/1991
KABIKINASE - PWS 250000 UNIT/VIAL	pharmacia & upjohn inc	02126125	Powder For Solution - Intracoronary , Intravenous	250000 UNIT / VIAL	12/31/1995
STREPTASE	csl behring canada inc	02019019	Powder For Solution - Intravenous , Intracoronary	1500000 UNIT / VIAL	12/31/1994
KABIKINASE - PWS 1500000UNITS/VIAL	pharmacia & upjohn inc	02126141	Powder For Solution - Intravenous , Intracoronary	1500000 UNIT / VIAL	12/31/1995
KABIKINASE - PWS 750000UNITS/VIAL	pharmacia & upjohn inc	02126133	Powder For Solution - Intracoronary , Intravenous	750000 UNIT / VIAL	12/31/1995

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
ERNODASA	Laboratorios Ern S.A.	55215	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica	Commercialized
VARIDASA COMPRIMIDOS	Industrial Farmaceutica Cantabria S.A.	41161	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access